# Rubicon Organics and 4C Labs Launch Medical Cannabis Products in the UK > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/medical-cannabis-products-uk-1964-supply-co-launch/ > **Published:** 2026-04-13T06:11:17-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:23:51-04:00 > **Clinical Summary:** Discover the launch of medical cannabis products UK by 1964 Supply Co, expanding access to regulated cannabis in the UK market. --- ✦ New CED Clinical Relevance  #84High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News  |  CED Clinic International AccessProduct QualityRegulatory FrameworkMarket ExpansionTreatment Continuity Why This Matters Market expansion into the UK represents growing global access to regulated [medical cannabis products](https://cedclinic.com/cannabis-infused-products-skin-diy-topical-recipes/), which affects patient treatment options and clinical decision-making frameworks. The involvement of established cannabis companies in regulated medical markets signals maturation of quality control and standardization processes that clinicians rely on for consistent dosing. Clinical Summary Rubicon Organics and 4C Labs have launched 1964 Supply Co. [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) products in the UK market, expanding regulated [medical cannabis access](https://cedclinic.com/medical-marijuana-card-reciprocity/) in a jurisdiction with established prescription pathways. The UK allows specialist physicians to prescribe medical cannabis for specific conditions when conventional treatments have been inadequate. This market entry represents commercial scaling of [medical cannabis products](https://cedclinic.com/cannabis-infused-products-skin-diy-topical-recipes/) in a regulatory framework that requires pharmaceutical-grade manufacturing standards and clinical oversight. Dr. Caplan’s Take “More regulated markets mean more standardized products, which is fundamentally good for [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/). When cannabis companies can operate within established medical frameworks, we get better consistency in what we’re actually prescribing to patients.” Clinical Perspective 🧠 Clinicians should recognize that expanding regulated markets create opportunities for more consistent product access and quality assurance. Patients traveling between jurisdictions may have better continuity of care as similar regulated products become available across borders. This development doesn’t change current prescribing considerations but may improve long-term treatment planning and product reliability. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Rubicon%20Organics%20Inc.%20and%204C%20Labs%20Launch%201964%20Supply%20Co.%20Medical%20Cannabis%20Produc...%20%40drcaplan&url=https%3A//www.marketscreener.com/news/rubicon-organics-inc-and-4c-labs-launch-1964-supply-co-medical-cannabis-products-in-the-u-k-ce7e50d9d08ff521)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.marketscreener.com/news/rubicon-organics-inc-and-4c-labs-launch-1964-supply-co-medical-cannabis-products-in-the-u-k-ce7e50d9d08ff521)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Rubicon%20Organics%20Inc.%20and%204C%20Labs%20Launch%201964%20Supply%20Co.%20Medical%20Cannabis%20Produc...%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.marketscreener.com/news/rubicon-organics-inc-and-4c-labs-launch-1964-supply-co-medical-cannabis-products-in-the-u-k-ce7e50d9d08ff521)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.marketscreener.com/news/rubicon-organics-inc-and-4c-labs-launch-1964-supply-co-medical-cannabis-products-in-the-u-k-ce7e50d9d08ff521](https://www.marketscreener.com/news/rubicon-organics-inc-and-4c-labs-launch-1964-supply-co-medical-cannabis-products-in-the-u-k-ce7e50d9d08ff521) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating of this cannabis news?](#What_is_the_clinical_relevance_rating_of_this_cannabis_news) - [What key areas does this cannabis news cover?](#What_key_areas_does_this_cannabis_news_cover) - [Is this information new or recently updated?](#Is_this_information_new_or_recently_updated) - [What type of clinical implications might this news have?](#What_type_of_clinical_implications_might_this_news_have) - [Who would benefit most from reading this cannabis news?](#Who_would_benefit_most_from_reading_this_cannabis_news) - [Related](#Related) ## FAQ #### What is the clinical relevance rating of this cannabis news? This article has been assigned a “High Clinical Relevance” rating (#84) by CED Clinical. This indicates strong evidence or policy relevance with direct clinical implications for medical cannabis practice. #### What key areas does this cannabis news cover? The news covers four main areas: International Access, Product Quality, Regulatory Framework, and Market Expansion. These topics suggest comprehensive coverage of medical cannabis policy and access issues. #### Is this information new or recently updated? Yes, this article is marked as “New” content from CED Clinic. This indicates recently published information relevant to current cannabis policy or clinical practice developments. #### What type of clinical implications might this news have? Given the high clinical relevance rating and topic areas, this likely impacts patient access to medical cannabis, product standards, and regulatory compliance. Healthcare providers may need to consider these developments when treating patients with medical cannabis. #### Who would benefit most from reading this cannabis news? This information would be most valuable for healthcare providers, medical cannabis patients, policy makers, and industry professionals. The clinical relevance rating suggests particular importance for medical practitioners working with cannabis therapeutics. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [First medical cannabis dispensary opening in Alabama in May | WHNT.com](https://cedclinic.com/alabama-medical-cannabis-program-launch-may-2024/) Learn about the first medical cannabis dispensary opening in Alabama, marking a milestone in regulated cannabis access in the US. [Read More](https://cedclinic.com/alabama-medical-cannabis-program-launch-may-2024/) [Medical Cannabis Commission approves cultivators, but manufacturer process remains unclear](https://cedclinic.com/2026-cannabis-manufacturing-standards-patient-safety/) Explore recent developments in medical cannabis regulation focusing on cultivator approvals and manufacturing challenges. [Explore Details](https://cedclinic.com/2026-cannabis-manufacturing-standards-patient-safety/) A decade after legalization, pot regulations need reform – The Boston Globe Understand ongoing regulatory challenges and reform needs in the cannabis industry a decade after legalization. Learn More ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).